- Home
- EXEL vs REGCO Comparison
EXEL vs REGCO Comparison
Compare EXEL & REGCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- REGCO
- Stock Information
- Founded
- EXEL 1994
- REGCO N/A
- Country
- EXEL United States
- REGCO United States
- Employees
- EXEL N/A
- REGCO 500
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- REGCO
- Sector
- EXEL Health Care
- REGCO
- Exchange
- EXEL Nasdaq
- REGCO Nasdaq
- Market Cap
- EXEL 9.8B
- REGCO N/A
- IPO Year
- EXEL 2000
- REGCO N/A
- Fundamental
- Price
- EXEL $37.43
- REGCO $22.61
- Analyst Decision
- EXEL Buy
- REGCO
- Analyst Count
- EXEL 18
- REGCO 0
- Target Price
- EXEL $37.59
- REGCO N/A
- AVG Volume (30 Days)
- EXEL 2.4M
- REGCO N/A
- Earning Date
- EXEL 05-02-2025
- REGCO N/A
- Dividend Yield
- EXEL N/A
- REGCO N/A
- EPS Growth
- EXEL 170.77
- REGCO N/A
- EPS
- EXEL 1.76
- REGCO N/A
- Revenue
- EXEL $2,168,701,000.00
- REGCO N/A
- Revenue This Year
- EXEL $5.82
- REGCO N/A
- Revenue Next Year
- EXEL $10.81
- REGCO N/A
- P/E Ratio
- EXEL $21.27
- REGCO N/A
- Revenue Growth
- EXEL 18.50
- REGCO N/A
- 52 Week Low
- EXEL $20.14
- REGCO N/A
- 52 Week High
- EXEL $40.02
- REGCO N/A
- Technical
- Relative Strength Index (RSI)
- EXEL 57.87
- REGCO 56.85
- Support Level
- EXEL $35.34
- REGCO $22.37
- Resistance Level
- EXEL $37.67
- REGCO $22.75
- Average True Range (ATR)
- EXEL 1.32
- REGCO 0.34
- MACD
- EXEL 0.22
- REGCO 0.08
- Stochastic Oscillator
- EXEL 95.46
- REGCO 69.09
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About REGCO Regency Centers Corporation 5.875% Series B Cumulative Redeemable Preferred Stock
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 483 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.